

1.18 Release Notes

Information

New Batch/Lot

An update to the software specification has been issued by NHS Digital including JCVI guidance in supporting vaccinations to 'at-risk' 5-11 year old children. The cohort eligibility will be based on age and clinical circumstances of individuals. This release of eVacc has been primarily developed in order to meet the recording requirements. Below are details outlining the changes made and how they may affect your day to day recording of vaccinations.

COVID Vaccination - Batch Management

EF-2724 Addition of Comirnaty® Children 5-11 years vaccine

A new paediatric Comirnaty® Manufacturer and Type COVID-19 vaccine has been Comirnaty® Children 5-11 years (Paediatric Pfizer) released by Pfizer. This will now Comirnaty Children 5-11 years COVID-19 mRNA Vaccine appear in the drop down selection 10micrograms/0.2ml dose concentrate for dispersion for injection of vaccines within Batch multidose vials (Pfizer Ltd) 10 dose Management. Batch/Lot Number The Batch/Lot Number has the AA0000 same format as the adult Comirnaty® (PfizerBioNtech) vaccine. Expiry Date DD/MM/YYYY Use by DD/MM/YYYY HH:mm 31/03/2022 30/04/2022 12:00 On defrosting the Comirnaty® Children 5-11 years (Paediatric Pfizer) vaccine must be used within 70 days 0 hours

[EF-2741] - Defrost warning for Paediatric Pfizer in batch add

The Comirnaty® Children 5-11 years (Paediatric Pfizer) has a different useful life of 70 days following defrost when compared to the Comirnaty® (PfizerBioNtech) vaccine. This is reflected in the information text shown in the above image.



[EF-2726] - Addition of a Dose Amount to Comirnaty® (PfizerBioNtech)

The new vaccine released for children (Comirnaty® Children 5-11 years (Paediatric Pfizer) 0.2ml), has a differing standard dose in comparison to the adult vaccine. Should a vaccinator select the adult vaccine for use with a child aged between 5 and 11 years and additional dose will be available within the selector of 0.1ml. By default this will be selected however can be modified in the event that an alternate dose has been given.

Vaccine Name	Vaccine Type	Batch Number Format(s)	Additional Information	Status	Authorised Age
Comirnaty® (PfizerBioNtech)	mRNA	AAnnnn	 The existing batch numbers for the Pfizer vaccine starts with 'E' followed by another alphabetic character, and 4 numbers – e.g. EP1234 No known changes expected to Pfizer batch number formats 	Existing	5+
Comirnaty® Children 5-11 years (Paediatric Pfizer)	mRNA	AAnnnn	Same batch number configuration as seen on current Comirnaty product for January '22 delivery	New	5-11

The additions are now available within eVacc and you will notice subtle changes when these vaccines have been selected within the **Screening and Consent** and **Vaccination** templates. These changes are in the form of a warning message, description of the Vaccine Type and the dose amount for the selected vaccine. The dose amount in the **Vaccination** template has been configured to be selected according to the vaccine and age of the patient.

[EF-2725] - Addition of Children (5-11 years) Dosing and Schedule Information

As shown below the primary course dose amount for a child aged between 5 and 11 years is **0.1ml** for the **Comirnaty®** (**PfizerBioNtech**) and **0.2ml** for the **Comirnaty® Children 5-11 years** (**Paediatric Pfizer**)


Scheduling					Dose Amounts	
Vaccine Name	Minimum interval between 1 st and 2 nd dose	Minimum interval between 2 nd and subsequent primary course doses where required [1]	Minimum interval between primary course and booster doses [2]	Minimum interval between booster doses [2]	Primary course	Booster dose
Comirnaty® (PfizerBioNtech)	56 days	56 days	N/A	N/A	0.1ml	N/A
Comirnaty® Children 5-11 years (Paediatric Pfizer)	56 days	56 days	N/A	N/A	0.2ml	N/A
AstraZeneca [3]	N/A	N/A	N/A	N/A	N/A	N/A
Spikevax® [3] (Moderna)	N/A	N/A	N/A	N/A	N/A	N/A



COVID - Screening and Consent, Vaccination Templates

[EF-2719] - Under 5 Years of Age NEW Warning

A warning message will be displayed if the patient being vaccinated is under 5 years of age regardless of which vaccine has been selected.




[EF-2720] - Under 12 Years of Age Update to Current Warning

If a patient is under the age of 12, and one of the following vaccines has been selected,

- Spikevax® (Moderna) 0.25ml & 0.5ml
- AstraZeneca 0.5ml
- Comirnaty® (PfizerBioNtech) **0.3ml only**

Then a further warning message is displayed:





[EF-2721] - Over 12 Years of Age child dose Comirnaty Warning

With the addition of the Comirnaty® Children 5-11 years (Paediatric Pfizer) 0.2ml vaccine, and a dose of Comirnaty® (Pfizer BioNTech) 0.1ml (for patients aged 5 - 11 years), a warning message will be displayed if the patient is 12 years of age or over.

(1) You have selected Comirnaty® Children 5-11 years (Paediatric Pfizer) - 0.2 ml for a patient who is 12 years or older. Please discuss this with a Responsible Clinician before continuing as this should only be administered where deemed clinically appropriate.

[EF-2723] - Update to Caution Checklist Warning Text

The question "Has the individual indicated they are, or could be pregnant?" within the screening and consent form has been removed if the patient is under the age of 12 years inline with NHS guidance.

Cautions							
☐ Has the individual had any vaccination in the last 7 days?							
Has the individual informed you they are currently or have been in a trial of a potential coronavirus vaccine?							
$\ \square$ Is the individual taking anticoagulant medication, or do they have a bleeding disorder?							
☐ Does the individual currently have any symptoms of Covid-19 infection?							
Is the individual suitable to receive a vaccine today?	Yes	No					

[EF-2722] - Update to Exclusion Checklist Warning Text

Exclusion Checklist question: "Has the individual had any covid symptoms or tested positive to covid over the last 'n' weeks?" (with 'n' being either 4 or 12 depending on the patient's age), to include the text "see precautions Immunisation against infectious Diseases (The Green Book)." at the end of the message displayed if 'Yes' is answered to the question.

☑ Has the individual had any covid symptoms or tested positive to covid over the last 4 weeks?

You have indicated that this patient may not be clinically suitable. Confirmation required from lead clinician that patient is suitable for vaccination before proceeding, see precautions Immunisation against infectious Diseases (The Green Book)

[EF-2728] - Ensure booster warnings apply to applicable 5 - 15 year olds

With the addition of the new vaccine, dose amounts and dose schedule, the eVacc solution has had a number of "conditions" added so the relevant warnings are displayed when a **Booster** course is selected for patients aged 5 to 15 years.




[EF-2715] - Update to various templates to standardise "responsible clinician" terminology

The Screening & Consent template contained a label of "Patient Screened by" and within the Journal view of a Screening & Consent Card there was a label of "Screened by".

To conform to the NHS Digital standardised wording, these two labels have now been renamed as "Responsible Clinician".

• Screening & Consent Template Now Displays



[EF-2729] - Human Readable Report updates

Within eVacc there is a report option to download a report for vaccination encounters that have taken place between two dates. The report contained a column heading of "Eligible child aged 12-15" which has now been amended to reflect the recent additions and now reads, "Eligible child aged 5-15"

[EF-2727] - Change to definition used for Supplementary Payment for Eligible 5-15 (Roving at a Residential Facility)

In conjunction with the update to the Human Readable Reports the Supplementary Payment definition has been updated to include all `at-risk` patients aged 5-15 years of age.